Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 374

1.

Robotic-assisted surgery compared with laparoscopic resection surgery for rectal cancer: the ROLARR RCT.

Jayne D, Pigazzi A, Marshall H, Croft J, Corrigan N, Copeland J, Quirke P, West N, Edlin R, Hulme C, Brown J.

Southampton (UK): NIHR Journals Library; 2019 Sep.

2.

Ex-vivo specimen MRI and pathology confirm a recto-sigmoid mesenteric waist at the junction of the mesorectum and mesocolon.

D'Souza N, Lord A, Shaw A, Patel A, Balyasnikova S, Tudyka V, Abulafi M, Moran B, Rasheed S, Tekkis P, Coffey JC, Terlizzo M, West NP, Quirke P, Brown G.

Colorectal Dis. 2019 Sep 19. doi: 10.1111/codi.14856. [Epub ahead of print]

PMID:
31535423
3.

The role of the longitudinal muscle in the anal sphincter complex: Implications for the Intersphincteric Plane in Low Rectal Cancer Surgery?

Kraima AC, West NP, Roberts N, Magee DR, Smit NN, van de Velde CJH, DeRuiter MC, Rutten HJ, Quirke P.

Clin Anat. 2019 Aug 5. doi: 10.1002/ca.23444. [Epub ahead of print]

PMID:
31385374
4.

Radiologist and multidisciplinary team clinician opinions on the quality of MRI rectal cancer staging reports: how are we doing?

Brown PJ, Rossington H, Taylor J, Lambregts DMJ, Morris EJA, West NP, Quirke P, Tolan D; YCR BCIP Study Group.

Clin Radiol. 2019 Aug;74(8):637-642. doi: 10.1016/j.crad.2019.04.015. Epub 2019 May 11.

PMID:
31084973
5.

Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial.

Barrow P, Richman SD, Wallace AJ, Handley K, Hutchins GGA, Kerr D, Magill L, Evans DG, Gray R, Quirke P, Hill J.

Histopathology. 2019 Aug;75(2):236-246. doi: 10.1111/his.13895. Epub 2019 Jul 5.

6.

Standardised reports with a template format are superior to free text reports: the case for rectal cancer reporting in clinical practice.

Brown PJ, Rossington H, Taylor J, Lambregts DMJ, Morris E, West NP, Quirke P, Tolan D; YCR BCIP Study Group.

Eur Radiol. 2019 Sep;29(9):5121-5128. doi: 10.1007/s00330-019-06028-8. Epub 2019 Feb 22.

7.

Additional loss of MSH2 and MSH6 expression in sporadic deficient mismatch repair colorectal cancer due to MLH1 promoter hypermethylation.

Westwood A, Glover A, Hutchins G, Young C, Brockmoeller S, Robinson R, Worrilow L, Wallace D, Rankeillor K, Adlard J, Quirke P, West N.

J Clin Pathol. 2019 Jun;72(6):443-447. doi: 10.1136/jclinpath-2018-205687. Epub 2019 Feb 5.

8.

BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC).

Glynne-Jones R, Hall MR, Lopes A, Pearce S, Goh V, Bosompem S, Bridgewater J, Chau I, Wasan H, Moran B, Melcher L, West NP, Quirke P, Wong WL, Beare S, Hava N, Duggan M, Harrison M.

Heliyon. 2018 Sep 22;4(9):e00804. doi: 10.1016/j.heliyon.2018.e00804. eCollection 2018 Sep.

9.

A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS.

Gollins S, West N, Sebag-Montefiore D, Susnerwala S, Falk S, Brown N, Saunders M, Quirke P, Ray R, Parsons P, Griffiths G, Maughan T, Adams R, Hurt C.

Br J Cancer. 2018 Sep;119(6):697-706. doi: 10.1038/s41416-018-0209-4. Epub 2018 Aug 17.

10.

Colon cancer surgery: pathological quality control is essential for optimal outcomes.

West NP, Quirke P.

Colorectal Dis. 2018 May;20 Suppl 1:34-35. doi: 10.1111/codi.14075.

11.

Fixation and Spread of Somatic Mutations in Adult Human Colonic Epithelium.

Nicholson AM, Olpe C, Hoyle A, Thorsen AS, Rus T, Colombé M, Brunton-Sim R, Kemp R, Marks K, Quirke P, Malhotra S, Ten Hoopen R, Ibrahim A, Lindskog C, Myers MB, Parsons B, Tavaré S, Wilkinson M, Morrissey E, Winton DJ.

Cell Stem Cell. 2018 Jun 1;22(6):909-918.e8. doi: 10.1016/j.stem.2018.04.020. Epub 2018 May 17.

12.

IntAct: intra-operative fluorescence angiography to prevent anastomotic leak in rectal cancer surgery: a randomized controlled trial.

Armstrong G, Croft J, Corrigan N, Brown JM, Goh V, Quirke P, Hulme C, Tolan D, Kirby A, Cahill R, O'Connell PR, Miskovic D, Coleman M, Jayne D.

Colorectal Dis. 2018 Aug;20(8):O226-O234. doi: 10.1111/codi.14257. Epub 2018 Jun 8.

13.

No Significant Association Between the Fecal Microbiome and the Presence of Irritable Bowel Syndrome-type Symptoms in Patients with Quiescent Inflammatory Bowel Disease.

Shutkever O, Gracie DJ, Young C, Wood HM, Taylor M, John Hamlin P, Ford AC, Quirke P.

Inflamm Bowel Dis. 2018 Jun 8;24(7):1597-1605. doi: 10.1093/ibd/izy052.

14.

Clinicopathological, genomic and immunological factors in colorectal cancer prognosis.

Marks KM, West NP, Morris E, Quirke P.

Br J Surg. 2018 Jan;105(2):e99-e109. doi: 10.1002/bjs.10756. Review.

PMID:
29341159
15.

Can we Save the rectum by watchful waiting or TransAnal microsurgery following (chemo) Radiotherapy versus Total mesorectal excision for early REctal Cancer (STAR-TREC study)?: protocol for a multicentre, randomised feasibility study.

Rombouts AJM, Al-Najami I, Abbott NL, Appelt A, Baatrup G, Bach S, Bhangu A, Garm Spindler KL, Gray R, Handley K, Kaur M, Kerkhof E, Kronborg CJ, Magill L, Marijnen CAM, Nagtegaal ID, Nyvang L, Peters FP, Pfeiffer P, Punt C, Quirke P, Sebag-Montefiore D, Teo M, West N, de Wilt JHW; for STAR-TREC Collaborative Group.

BMJ Open. 2017 Dec 28;7(12):e019474. doi: 10.1136/bmjopen-2017-019474.

16.

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.

Adams R, Brown E, Brown L, Butler R, Falk S, Fisher D, Kaplan R, Quirke P, Richman S, Samuel L, Seligmann J, Seymour M, Shiu KK, Wasan H, Wilson R, Maughan T; FOCUS4 Trial Investigators.

Lancet Gastroenterol Hepatol. 2018 Mar;3(3):162-171. doi: 10.1016/S2468-1253(17)30394-1. Epub 2017 Dec 16.

17.

Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer.

Seligmann JF, Hatch AJ, Richman SD, Elliott F, Jacobs B, Brown S, Hurwitz H, Barrett JH, Quirke P, Nixon AB, Seymour MT.

JAMA Oncol. 2018 Apr 1;4(4):564-568. doi: 10.1001/jamaoncol.2017.3168.

18.

Internal anal sphincter nerves - a macroanatomical and microscopic description of the extrinsic autonomic nerve supply of the internal anal sphincter.

Stelzner S, Böttner M, Kupsch J, Kneist W, Quirke P, West NP, Witzigmann H, Wedel T.

Colorectal Dis. 2018 Jan;20(1):O7-O16. doi: 10.1111/codi.13942.

19.

Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer: The ROLARR Randomized Clinical Trial.

Jayne D, Pigazzi A, Marshall H, Croft J, Corrigan N, Copeland J, Quirke P, West N, Rautio T, Thomassen N, Tilney H, Gudgeon M, Bianchi PP, Edlin R, Hulme C, Brown J.

JAMA. 2017 Oct 24;318(16):1569-1580. doi: 10.1001/jama.2017.7219.

20.

Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer.

Bosch LJW, Trooskens G, Snaebjornsson P, Coupé VMH, Mongera S, Haan JC, Richman SD, Koopman M, Tol J, de Meyer T, Louwagie J, Dehaspe L, van Grieken NCT, Ylstra B, Verheul HMW, van Engeland M, Nagtegaal ID, Herman JG, Quirke P, Seymour MT, Punt CJA, van Criekinge W, Carvalho B, Meijer GA.

Oncotarget. 2017 Jun 27;8(38):63140-63154. doi: 10.18632/oncotarget.18702. eCollection 2017 Sep 8.

21.

A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota.

Watson H, Mitra S, Croden FC, Taylor M, Wood HM, Perry SL, Spencer JA, Quirke P, Toogood GJ, Lawton CL, Dye L, Loadman PM, Hull MA.

Gut. 2018 Nov;67(11):1974-1983. doi: 10.1136/gutjnl-2017-314968. Epub 2017 Sep 26.

22.

Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.

Gollins S, West N, Sebag-Montefiore D, Myint AS, Saunders M, Susnerwala S, Quirke P, Essapen S, Samuel L, Sizer B, Worlding J, Southward K, Hemmings G, Tinkler-Hundal E, Taylor M, Bottomley D, Chambers P, Lawrie E, Lopes A, Beare S.

Br J Cancer. 2017 Oct 24;117(9):1286-1294. doi: 10.1038/bjc.2017.294. Epub 2017 Aug 31.

23.

A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial.

Battersby NJ, Dattani M, Rao S, Cunningham D, Tait D, Adams R, Moran BJ, Khakoo S, Tekkis P, Rasheed S, Mirnezami A, Quirke P, West NP, Nagtegaal I, Chong I, Sadanandam A, Valeri N, Thomas K, Frost M, Brown G.

Trials. 2017 Aug 29;18(1):394. doi: 10.1186/s13063-017-2085-2.

24.

The effect of a multidisciplinary regional educational programme on the quality of colon cancer resection.

Sheehan-Dare GE, Marks KM, Tinkler-Hundal E, Ingeholm P, Bertelsen CA, Quirke P, West NP.

Colorectal Dis. 2018 Feb;20(2):105-115. doi: 10.1111/codi.13830.

25.

Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer.

Hutchins GGA, Treanor D, Wright A, Handley K, Magill L, Tinkler-Hundal E, Southward K, Seymour M, Kerr D, Gray R, Quirke P; QUASAR trial collaborators and the UK National Cancer Research Institute Colorectal Cancer Clinical Studies Group.

Histopathology. 2018 Feb;72(3):391-404. doi: 10.1111/his.13326. Epub 2017 Nov 27.

26.

Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Pathology Standards and Datasets.

Langman G, Loughrey M, Shepherd N, Quirke P.

Colorectal Dis. 2017 Jul;19 Suppl 1:74-81. doi: 10.1111/codi.13708. No abstract available.

PMID:
28632310
27.

Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.

Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, El Zimaity H, Fléjou JF, Hansen TP, Hartmann A, Kakar S, Langner C, Nagtegaal I, Puppa G, Riddell R, Ristimäki A, Sheahan K, Smyrk T, Sugihara K, Terris B, Ueno H, Vieth M, Zlobec I, Quirke P.

Mod Pathol. 2017 Sep;30(9):1299-1311. doi: 10.1038/modpathol.2017.46. Epub 2017 May 26. Review.

28.

Urgent improvements needed to diagnose and manage Lynch syndrome.

Monahan KJ, Alsina D, Bach S, Buchanan J, Burn J, Clark S, Dawson P, De Souza B, Din FV, Dolwani S, Dunlop MG, East J, Evans DG, Fearnhead N, Frayling IM, Glynne-Jones R, Hill J, Houlston R, Hull M, Lalloo F, Latchford A, Lishman S, Quirke P, Rees C, Rutter M, Sasieni P, Senapati A, Speake D, Thomas H, Tomlinson I.

BMJ. 2017 Mar 20;356:j1388. doi: 10.1136/bmj.j1388. No abstract available.

29.

Comparing mutation calls in fixed tumour samples between the affymetrix OncoScan® array and PCR based next-generation sequencing.

Wood HM, Foster JM, Taylor M, Tinkler-Hundal E, Togneri FS, Wojtowicz P, Oumie A, Spink KG, Brew F, Quirke P.

BMC Med Genomics. 2017 Mar 18;10(1):17. doi: 10.1186/s12920-017-0254-5.

30.

Tumor Deposits in Colorectal Cancer: Improving the Value of Modern Staging-A Systematic Review and Meta-Analysis.

Nagtegaal ID, Knijn N, Hugen N, Marshall HC, Sugihara K, Tot T, Ueno H, Quirke P.

J Clin Oncol. 2017 Apr 1;35(10):1119-1127. doi: 10.1200/JCO.2016.68.9091. Epub 2016 Dec 28. Review.

31.

Examining the potential use and long-term stability of guaiac faecal occult blood test cards for microbial DNA 16S rRNA sequencing.

Taylor M, Wood HM, Halloran SP, Quirke P.

J Clin Pathol. 2017 Jul;70(7):600-606. doi: 10.1136/jclinpath-2016-204165. Epub 2016 Dec 23.

32.

Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials.

Seligmann JF, Fisher D, Smith CG, Richman SD, Elliott F, Brown S, Adams R, Maughan T, Quirke P, Cheadle J, Seymour M, Middleton G.

Ann Oncol. 2017 Mar 1;28(3):562-568. doi: 10.1093/annonc/mdw645.

33.

A retrospective observational study of length of stay in hospital after colorectal cancer surgery in England (1998-2010).

Aravani A, Samy EF, Thomas JD, Quirke P, Morris EJ, Finan PJ.

Medicine (Baltimore). 2016 Nov;95(47):e5064.

34.

Protocol for a multicentre randomised feasibility trial evaluating early Surgery Alone In LOw Rectal cancer (SAILOR).

Harris DA, Thorne K, Hutchings H, Islam S, Holland G, Hatcher O, Gwynne S, Jenkins I, Coyne P, Duff M, Feldman M, Winter DC, Gollins S, Quirke P, West N, Brown G, Fitzsimmons D, Brown A, Beynon J.

BMJ Open. 2016 Nov 21;6(11):e012496. doi: 10.1136/bmjopen-2016-012496.

35.

Challenging diagnostic issues in adenomatous polyps with epithelial misplacement in bowel cancer screening: 5 years' experience of the Bowel Cancer Screening Programme Expert Board.

Griggs RK, Novelli MR, Sanders DS, Warren BF, Williams GT, Quirke P, Shepherd NA.

Histopathology. 2017 Feb;70(3):466-472. doi: 10.1111/his.13092. Epub 2016 Nov 15.

36.

Significant Individual Variation Between Pathologists in the Evaluation of Colon Cancer Specimens After Complete Mesocolic Excision.

Munkedal DL, Laurberg S, Hagemann-Madsen R, Stribolt KJ, Krag SR, Quirke P, West NP.

Dis Colon Rectum. 2016 Oct;59(10):953-61. doi: 10.1097/DCR.0000000000000671.

37.

Next Generation intraoperative Lymph node staging for Stratified colon cancer surgery (GLiSten): a multicentre, multinational feasibility study of fluorescence in predicting lymph node-positive disease.

Andrew H, Gossedge G, Croft J, Corrigan N, Brown JM, West N, Quirke P, Tolan D, Cahill R, Jayne DG.

Southampton (UK): NIHR Journals Library; 2016 Aug.

38.

Reply to D.J. Sargent et al.

Glimelius B, Hohenberger WM, Matzel KE, Sugihara K, Quirke P.

J Clin Oncol. 2016 Oct 20;34(30):3713-3714. doi: 10.1200/JCO.2016.68.9323. No abstract available.

39.

Reply to: Does MRI Restaging of Rectal Cancer After Chemoradiotherapy Actually Permit a Change in Surgical Management?

Battersby NJ, Moran B, Stelzner S, West NP, Branagan G, Strassburg J, Quirke P, Dattani M, Tekkis P, Ginnerup Pedersen B, Hagemann-Madsen GTR, Gudgeon M, Heald B, Brown G.

Ann Surg. 2017 Dec;266(6):e116-e118. doi: 10.1097/SLA.0000000000001791. No abstract available.

PMID:
27232254
40.

Identification of 42 Genes Linked to Stage II Colorectal Cancer Metastatic Relapse.

Al-Temaimi RA, Tan TZ, Marafie MJ, Thiery JP, Quirke P, Al-Mulla F.

Int J Mol Sci. 2016 Apr 28;17(5). pii: E598. doi: 10.3390/ijms17050598.

41.

Wide Variation in the Use of Radiotherapy in the Management of Surgically Treated Rectal Cancer Across the English National Health Service.

Morris EJ, Finan PJ, Spencer K, Geh I, Crellin A, Quirke P, Thomas JD, Lawton S, Adams R, Sebag-Montefiore D.

Clin Oncol (R Coll Radiol). 2016 Aug;28(8):522-31. doi: 10.1016/j.clon.2016.02.002. Epub 2016 Feb 28.

42.

Should the Benefit of Adjuvant Chemotherapy in Colon Cancer Be Re-Evaluated?

Påhlman LA, Hohenberger WM, Matzel K, Sugihara K, Quirke P, Glimelius B.

J Clin Oncol. 2016 Apr 20;34(12):1297-9. doi: 10.1200/JCO.2015.65.3048. Epub 2016 Feb 22. No abstract available.

43.

Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.

Seligmann JF, Elliott F, Richman SD, Jacobs B, Hemmings G, Brown S, Barrett JH, Tejpar S, Quirke P, Seymour MT.

JAMA Oncol. 2016 May 1;2(5):633-642. doi: 10.1001/jamaoncol.2015.6065.

PMID:
26867820
44.

Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer.

Hill EJ, Roberts C, Franklin JM, Enescu M, West N, MacGregor TP, Chu KY, Boyle L, Blesing C, Wang LM, Mukherjee S, Anderson EM, Brown G, Dutton S, Love SB, Schnabel JA, Quirke P, Muschel R, McKenna WG, Partridge M, Sharma RA.

Clin Cancer Res. 2016 Apr 15;22(8):1922-31. doi: 10.1158/1078-0432.CCR-15-1489. Epub 2016 Feb 9.

45.

The Authors Reply.

Toh EW, Quirke P.

Dis Colon Rectum. 2016 Feb;59(2):e19-20. doi: 10.1097/DCR.0000000000000538. No abstract available.

PMID:
26734980
46.

HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.

Richman SD, Southward K, Chambers P, Cross D, Barrett J, Hemmings G, Taylor M, Wood H, Hutchins G, Foster JM, Oumie A, Spink KG, Brown SR, Jones M, Kerr D, Handley K, Gray R, Seymour M, Quirke P.

J Pathol. 2016 Mar;238(4):562-70. doi: 10.1002/path.4679. Epub 2016 Jan 29.

47.

Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum.

Glynne-Jones R, Hava N, Goh V, Bosompem S, Bridgewater J, Chau I, Gaya A, Wasan H, Moran B, Melcher L, MacDonald A, Osborne M, Beare S, Jitlal M, Lopes A, Hall M, West N, Quirke P, Wong WL, Harrison M; Bacchus investigators.

BMC Cancer. 2015 Oct 23;15:764. doi: 10.1186/s12885-015-1764-1.

48.

Understanding the surgical pitfalls in total mesorectal excision: Investigating the histology of the perirectal fascia and the pelvic autonomic nerves.

Kraima AC, West NP, Treanor D, Magee DR, Bleys RL, Rutten HJ, van de Velde CJ, Quirke P, DeRuiter MC.

Eur J Surg Oncol. 2015 Dec;41(12):1621-9. doi: 10.1016/j.ejso.2015.08.166. Epub 2015 Sep 16.

49.

The anatomy of the perineal body in relation to abdominoperineal excision for low rectal cancer.

Kraima AC, West NP, Treanor D, Magee D, Roberts N, van de Velde CJ, DeRuiter MC, Quirke P, Rutten HJ.

Colorectal Dis. 2016 Jul;18(7):688-95. doi: 10.1111/codi.13138.

50.

Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial.

Richman SD, Adams R, Quirke P, Butler R, Hemmings G, Chambers P, Roberts H, James MD, Wozniak S, Bathia R, Pugh C, Maughan T, Jasani B; FOCUS4 Trial Management Group.

J Clin Pathol. 2016 Jan;69(1):35-41. doi: 10.1136/jclinpath-2015-203097. Epub 2015 Sep 7.

Supplemental Content

Loading ...
Support Center